SciClone Licenses New Ondansetron Forumulation From APR For Chinese, Vietnam Markets

SHANGHAI - California-based SciClone Pharmaceuticals inked an agreement with Switzerland-based Applied Pharma Research to license Ondansetron Rapidflim for China and Vietnam. Under the agreement, SciClone will pay APR $1 million plus milestone payments for marketing rights for 10 years following regulatory approval, according to SciClone

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip